Pay to Marwadi

Company Profile

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE1033.1524.45 (+2.42 % )
PREV CLOSE (Rs.) 1008.70
OPEN PRICE (Rs.) 1016.05
BID PRICE (QTY) 1032.95 (2 )
OFFER PRICE (QTY) 1033.85 (67 )
VOLUME 48595
TODAY'S LOW / HIGH (Rs.)1011.00 1041.10
52 WK LOW / HIGH (Rs.)482.55 1033.15
NSE1034.25 25.25 (+2.5 % )
PREV CLOSE(Rs.) 1009.00
OPEN PRICE (Rs.) 1014.95
BID PRICE (QTY) 1034.20 (156 )
OFFER PRICE (QTY) 1034.65 (53 )
VOLUME 1297085
TODAY'S LOW / HIGH(Rs.) 1009.20 1041.75
52 WK LOW / HIGH (Rs.)484.95 1033

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.59
TTM EPS (Rs.) 25.11
P/E Ratio 40.81
Book Value (Rs.) 143.63
Face Value (Rs.) 1
MCap (Rs. in Mn) 1031188.59
Price/Earning (TTM) 34.14
Price/Sales (TTM) 10.76
Price/Book (MRQ) 7.14
PAT Margin (%) 17.53
ROCE (%) 13.45
Incorporation Year : 1995

Management Info :

Pankaj R Patel - Chairman Sharvil P Patel - Managing Director

Registered Office :

Address : Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway,
Ahmedabad,
Gujarat-382481

Phone : 079-71800000 / 48040000

Registrar's Details : Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE, MCX
NEWS More
17May05-17-2024$Zydus Lifesciences’ arm signs exclusive licensing, supply agreement with MSN Laboratories Zydus Lifesciences’ arm si

Zydus Lifesciences’ wholly owned subsidiary -- Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market.

As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the Product in the US market. MSN was a first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences’ wholly owned subsidiary -- Zydus Lifescie..
17May05-17-2024$Zydus Lifesciences informs about press release Zydus Lifesciences informs a

Zydus Lifesciences has informed that it enclosed a copy of press release dated May 17, 2024 titled ‘Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX®) for the US market’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences has informed that it enclosed a copy of pres..
17May05-17-2024$Zydus Lifesciences surges as its arm signs exclusive licensing, supply agreement with MSN Laboratories Zydus Lifesciences surges as

Zydus Lifesciences is currently trading at Rs. 1024.20, up by 15.50 points or 1.54% from its previous closing of Rs. 1008.70 on the BSE.

The scrip opened at Rs. 1016.05 and has touched a high and low of Rs. 1026.05 and Rs. 1011.00 respectively. So far 5360 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1033.15 on 07-May-2024 and a 52 week low of Rs. 482.55 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 1026.05 and Rs. 970.45 respectively. The current market cap of the company is Rs. 101498.82 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.35% and 6.66% respectively.

Zydus Lifesciences’ wholly owned subsidiary -- Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market.

As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the Product in the US market. MSN was a first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences is currently trading at Rs. 1024.20, up by 1..
13May05-13-2024$BPCL, Hindalco Industries and Zydus Lifesciences to see some action today BPCL, Hindalco Industries an

Bharat Petroleum Corporation (BPCL) is planning to invest Rs 1.7 lakh crore over the next five years in its core oil refining, fuel marketing and petrochemical business as well as in clean energy such as hydrogen. As part of 'Project Aspire', a five-year strategic framework, BPCL plans to raise its oil refining capacity, augment petrochemical business and expand its presence in cleaner fuel space with an eye on energy transition and meeting country's fuel demand.

Indian Coast Guard (ICG) and Hindalco Industries have inked a Memorandum of Understanding (MoU) in New Delhi for the manufacturing and supply of indigenous marine-grade aluminium to Indian public and private shipyards for the construction of ships. The MoU will also provide benefits such as quarterly pricing, priority in supplies and Turnover discount.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Dexamethasone Tablets USP, 1 mg (USRLD: Dexamethasone Tablets). Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders. The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh.

Mahindra & Mahindra (M&M) has signed a Memorandum of Understanding (MoU) with the Ministry of Skill Development and Entrepreneurship (MSDE) to conduct two Pilots under the Drone Didi Yojna. Launched earlier this year, the scheme aims to train 15,000 women to operate drones for agricultural purposes such as fertiliser sowing, crop monitoring and seed sowing, thereby creating new livelihood opportunities for women through imparting skills in new technology areas.

RailTel Corporation of India has received the work order from Central Warehousing Corporation for Supply, Installation, Testing and Commissioning of Modern Video Surveillance System across India amounting to Rs 51,53,29,790 (Including Tax).

Lemon Tree Hotels has signed a new property-- Keys Select by Lemon Tree Hotels in Bareilly, Uttar Pradesh. The property, which will be franchised by Lemon Tree Hotels, is expected to open in FY25. Bareilly is a city in the northern Indian state of Uttar Pradesh, located near Ramganga. It is the seventh-largest metropolis of Uttar Pradesh and the 50th largest city of India. 

Vedanta has received approval for the acquisition of additional stake of 46.57% in AvanStrate Inc. (ASI) (an indirect subsidiary of the Company with 51.63% holding) from HOYA Corporation, Japan (HOYA) through Cairn India Holdings (CIHL), a wholly-owned subsidiary of the Company. Post the execution of the aforesaid transaction, CIHL will hold 98.2% in ASI. 

Bharat Petroleum Corporation (BPCL) is planning to invest Rs 1...
11May05-11-2024$Zydus Lifesciences gets final approval from USFDA for Dexamethasone Tablets Zydus Lifesciences gets fina

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Dexamethasone Tablets USP, 1 mg (USRLD: Dexamethasone Tablets).

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders. The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh.

Dexamethasone Tablets USP, 1 mg had annual sales of $1.8 million in the United States (IQVIA MAT March 24). The group now has 395 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences has received final approval from the United..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit450415292
Gross Profit 5743 20322
Operating Profit 805930028
Net Sales 2371387316
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 8852.00 (3.28%)
M.Cap ( in Cr)
20289.98
Astrazeneca Pharma I (BSE)
 5745.05 (1.88%)
M.Cap ( in Cr)
14220.00
Alkem Laboratories (BSE)
 5367.20 (0.95%)
M.Cap ( in Cr)
63322.22
Pfizer (BSE)
 4378.70 (0.99%)
M.Cap ( in Cr)
19966.37
RPG Life Sciences (BSE)
 1524.40 (1.66%)
M.Cap ( in Cr)
2493.75
Shareholding Pattern More
PROMOTERS 74.98 %
MUTUAL FUNDS/UTI 6.71 %
NON-INSTITUTION 6.66 %
FI/BANKS/INSURANCE 5.74 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes